Press Release Summary:
- Enhance real-time screening of iPSC-derived cardiomyocytes or neurons and G-protein-coupled receptors (GPCRs)
- Using ScreenWorks® Peak Pro 2 software device can translate higher resolution signals into key insights
- Capabilities allow scientists to support drug discovery and early safety evaluation using new iPSC-based models
Original Press Release:
Molecular Devices Introduces the FLIPR Penta System
Accelerate real-time screening of iPSC-derived cardiomyocytes or neurons, GPCRs, and ion channels
SAN JOSE, CALIF. (PRWEB) JULY 31, 2019 - Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System.
The new FLIPR Penta system builds on the success of the industry-leading FLIPR® platform for monitoring of G-protein-coupled receptors (GPCRs) and ion channels, offering a new high-speed camera option capable of capturing key dynamics of induced pluripotent stem cell (iPSC)-derived neuronal and cardiac cells at higher frame resolution. Additionally, the new ScreenWorks® Peak Pro 2 software adds capabilities to translate these higher resolution signals into key insights, adding over 30 new measurements to the analysis package.
"The expanded capabilities of the FLIPR Penta System will allow scientists studying stem cell-derived neuronal and cardiac cells to better characterize physiologic effects of compounds,” explains Sarah Vargas-Hurlston, Sr. Director of Product Marketing at Molecular Devices. “This new product builds on our established track record of providing complete high throughput screening solutions by adding capabilities to support drug discovery and early safety evaluation using new iPSC-based models."
For more information, visit http://www.moleculardevices.com.